{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:27:07Z","timestamp":1761920827883,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10549-020-06084-5","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T09:03:26Z","timestamp":1610701406000},"page":"259-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations"],"prefix":"10.1007","volume":"186","author":[{"given":"Hagit","family":"Shani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinat","family":"Bernstein-Molho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Laitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Netzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-1733","authenticated-orcid":false,"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"6084_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.suc.2020.02.012","volume":"100","author":"CV Cott","year":"2020","unstructured":"Cott CV (2020) Cancer genetics. Surg Clin 100:483\u2013498. https:\/\/doi.org\/10.1016\/j.suc.2020.02.012","journal-title":"Surg Clin"},{"key":"6084_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01148-2","author":"R Yoshida","year":"2020","unstructured":"Yoshida R (2020) Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. https:\/\/doi.org\/10.1007\/s12282-020-01148-2","journal-title":"Breast Cancer"},{"key":"6084_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1055\/s-0036-1579759","volume":"5","author":"H Correa","year":"2016","unstructured":"Correa H (2016) Li\u2013Fraumeni syndrome. J Pediatr Genet 5:84\u201388. https:\/\/doi.org\/10.1055\/s-0036-1579759","journal-title":"J Pediatr Genet"},{"key":"6084_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185\u2013187. https:\/\/doi.org\/10.1038\/ng1096-185","journal-title":"Nat Genet"},{"key":"6084_CR5","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1002\/cncr.33143","volume":"126","author":"EM Pinto","year":"2020","unstructured":"Pinto EM, Zambetti GP (2020) What 20 years of research has taught us about the TP53 p. R337H mutation. Cancer 126:4678\u20134686. https:\/\/doi.org\/10.1002\/cncr.33143","journal-title":"Cancer"},{"key":"6084_CR6","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1158\/0008-5472.CAN-20-1390","volume":"80","author":"J Powers","year":"2020","unstructured":"Powers J, Pinto EM, Barnoud T et al (2020) A rare TP53 mutation predominant in Ashkenazi Jews confers risk of multiple cancers. Cancer Res 80:3732\u20133744. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1390","journal-title":"Cancer Res"},{"key":"6084_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023\u20131031. https:\/\/doi.org\/10.1038\/nbt.2696","journal-title":"Nat Biotechnol"},{"key":"6084_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-014-3011-x","volume":"146","author":"K Bell","year":"2014","unstructured":"Bell K, Hodgson N, Levine M et al (2014) Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer. Breast Cancer Res Treat 146:447\u2013450. https:\/\/doi.org\/10.1007\/s10549-014-3011-x","journal-title":"Breast Cancer Res Treat"},{"key":"6084_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ejca.2006.09.024","volume":"43","author":"S Manoukian","year":"2007","unstructured":"Manoukian S, Peissel B, Pensotti V et al (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer\/sarcoma families. Eur J Cancer 43:601\u2013606. https:\/\/doi.org\/10.1016\/j.ejca.2006.09.024","journal-title":"Eur J Cancer"},{"key":"6084_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10689-007-9143-y","volume":"6","author":"C Monnerat","year":"2007","unstructured":"Monnerat C, Chompret A, Kannengiesser C et al (2007) BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer 6:453\u2013461. https:\/\/doi.org\/10.1007\/s10689-007-9143-y","journal-title":"Fam Cancer"},{"key":"6084_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jamaoncol.2015.4771","volume":"2","author":"J Whitworth","year":"2016","unstructured":"Whitworth J, Skytte A-B, Sunde L et al (2016) Multilocus inherited neoplasia alleles syndrome: a case series and review. JAMA Oncol 2:373\u2013379. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4771","journal-title":"JAMA Oncol"},{"key":"6084_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.gynor.2012.03.001","volume":"2","author":"P Gong","year":"2012","unstructured":"Gong P, Charles S, Rosenblum N et al (2012) A case of endometrial cancer in the context of a BRCA2 mutation and double heterozygosity for Lynch syndrome. Gynecol Oncol Case Rep 2:69\u201372. https:\/\/doi.org\/10.1016\/j.gynor.2012.03.001","journal-title":"Gynecol Oncol Case Rep"},{"key":"6084_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10689-007-9120-5","volume":"6","author":"AP Sokolenko","year":"2007","unstructured":"Sokolenko AP, Rozanov ME, Mitiushkina NV et al (2007) Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 6:281\u2013286. https:\/\/doi.org\/10.1007\/s10689-007-9120-5","journal-title":"Fam Cancer"},{"key":"6084_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10549-019-05343-4","volume":"177","author":"R Andr\u00e9s","year":"2019","unstructured":"Andr\u00e9s R, Menao S, Arruebo M et al (2019) Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report. Breast Cancer Res Treat 177:767\u2013770. https:\/\/doi.org\/10.1007\/s10549-019-05343-4","journal-title":"Breast Cancer Res Treat"},{"key":"6084_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10689-014-9747-y","volume":"14","author":"LB Ahlborn","year":"2015","unstructured":"Ahlborn LB, Steffensen AY, J\u00f8nson L et al (2015) Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations. Fam Cancer 14:129\u2013133. https:\/\/doi.org\/10.1007\/s10689-014-9747-y","journal-title":"Fam Cancer"},{"key":"6084_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ejca.2013.12.005","volume":"50","author":"D Bakry","year":"2014","unstructured":"Bakry D, Aronson M, Durno C et al (2014) Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 50:987\u2013996. https:\/\/doi.org\/10.1016\/j.ejca.2013.12.005","journal-title":"Eur J Cancer"},{"key":"6084_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.diff.2008.09.010","volume":"77","author":"SS Couto","year":"2009","unstructured":"Couto SS, Cao M, Duarte PC et al (2009) Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 77:103\u2013111. https:\/\/doi.org\/10.1016\/j.diff.2008.09.010","journal-title":"Differentiation"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-020-06084-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T13:05:19Z","timestamp":1615208719000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-020-06084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["6084"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-06084-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Sheba Ethics committee (SMC-1997-1947).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants consented, and signed an informed consent, as approved by the local ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Irrelevant.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}